Campaigners ask US govt to force down prices for common drugs
24-03-2022
FDA, FTC send message to biologics makers at competition workshop
10-03-2020
11-02-2020
sharafmaksumov / Shutterstock.com
Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bristol-Myers Squibb, Clarivate Analytics, Cortellis, BioMarin Pharmaceutical, haemophilia A, Valrox, gene therapy, The Medicines Company